Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_assertion type Assertion NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_head.
- NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_provenance.
- NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_assertion evidence source_evidence_literature NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_provenance.
- NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_assertion SIO_000772 16210092 NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_provenance.
- NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_assertion wasDerivedFrom befree-20140225 NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_provenance.
- NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_assertion wasGeneratedBy ECO_0000203 NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_provenance.